Abstract
The efficacy of thrombolytic therapy of acute ischemic stroke has recently been assessed by several clinical trials. Results suggest that intravenous rt-PA benefits carefully selected patients despite an increased risk of severe hemorrhagic transformation. This therapy should be used only by experienced physicians. Intravenous rt-PA for acute ischemic stroke has not yet been approved by European regulatory authorities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
